ArticleMolecular biology reports2026
Rational construction of rpsL or/and rpoB merodiploids affects biosynthesis of secondary metabolite in Streptomyces.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRibosome engineering technology typically involves resistance screening of streptomycin and rifampin to introduce point mutations in genes ribosomal protein S12 (rpsL) or RNA polymerase (rpoB), thereby enhancing the synthesis level of secondary metabolites in Streptomyces. Currently, directly introducing copies of genes rpsL and rpoB carrying "beneficial mutations" to construct diploids has become a more rapid and efficient method for obtaining high-yielding Streptomyces strains. METHODS AND
resultsWe directly introduced these beneficial mutations (rpsL: K88E/P91S; rpoB: S433L/H437Y/R440C) to construct single or combined merodiploids. Introducing rpsL-K88E promoted secondary metabolite biosynthesis in both strains S. coelicolor M145 and S. diastatochromogenes 1628, notably increasing tetramycin A production by 66% in 1628-rpsL-K88E. However, rpsL-P91S yielded no significant positive effects. Regarding rpoB, the M145-rpoB-H437Y strain showed a modest enhancement, with actinorhodin and undecylprodigiosin yields increasing by 20% and 22%. In S. diastatochromogenes 1628, introducing rpoB-H437Y, rpoB-R440C and rpoB-S433L promoted the synthesis of toyocamycin and tetraene macrolides to varying degrees.
conclusionsConstructing a diploid by directly introducing the rpsL and rpoB genes carrying "beneficial mutations" is an effective strategy to enhance the synthesis level of secondary metabolites, whether for the model strain S. coelicolor M145 or the industrial strain S. diastatochromogenes 1628.
Indexed as
Identifiers
42084699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.